It has just been reported that PHARMAC will be funding Strattera in New Zealand. Strattera is also known as Atomoxetine - and is a non-stimulant for the treatment of ADHD. Pharmac funding of Strattera will be `second line`, meaning that they will fund it if both of the stimulant medicines (i.e. ritalin and dexedrine) are not effective for ADHD for the individual, or cause significant side effects. While I am happy for the `Kiwis`to get access to this new medicine with funding, the se